

# ASPREE & ASPREE-XT

*International landmark aspirin studies*



Australia's largest clinical trial ASPREE (ASpirin in Reducing Events in the Elderly), last year revealed ground-breaking findings on the effect of daily low dose aspirin in 19,000 healthy older people aged >70+.

Our follow-up longitudinal study, ASPREE-XT, examines longer-term effects of aspirin on cancer, dementia, depression and physical disability. We also aim to identify the impact that medical conditions, lifestyle, the environment and genetics have on health, ageing and fragility in Australia and the US.

This is a rare opportunity to experience the broad range of study activities undertaken in large scale clinical research, or to focus on specific research interests, such as communications. Learn more about these studies at [aspre.org](http://aspre.org).

Join our team on placement by emailing [aspre@monash.edu](mailto:aspre@monash.edu)